{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:27Z","timestamp":1791169407291,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Philadelphia chromosome (Ph)\u2010positive B\u2010lymphoblastic leukemia exhibits immunophenotypic, karyotypic, and molecular genetic heterogeneity. The prognostic significance of these parameters was assessed in the context of intensive tyrosine kinase inhibitor (TKI)\u2010based chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The authors studied 65 adult patients with Ph\u2010positive acute lymphoblastic leukemia (ALL) who received treatment with TKI\u2010based therapy, correlated their clinicopathologic heterogeneity with patient outcome, and compared the findings with those from 60 adult patients with diploid B\u2010cell ALL who received similar chemotherapy without a TKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Ph\u2010positive ALL was associated with older age (\n                      <jats:italic>P<\/jats:italic>\n                      = .01), the common\u2010B immunophenotype characterized by a greater frequency of CD13 (alanine aminopeptidase) coexpression (\n                      <jats:italic>P<\/jats:italic>\n                      = .004), CD66c (carcinoembryonic antigen\u2010related cell adhesion molecule 3) expression (\n                      <jats:italic>P<\/jats:italic>\n                      = .007), and CD25 (interleukin\u20102 receptor alpha chain) expression (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001) and with a lower frequency of CD15 (3\u2010fucosyl\u2010N\u2010acetyl\u2010lactosamine) expression (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001). Conventional karyotypic analyses indicated that the Ph chromosome was the sole abnormality in 19 patients (30%), was present with other aberrancies in 43 patients (65%), and was absent (detectable only by fluorescence in situ hybridization [FISH] or quantitative reverse transcriptase\u2010polymerase chain reaction [RT\u2010PCR] analysis) in 3 patients (5%). The presence of the breakpoint cluster region\u2013v\u2010Abelson murine leukemia viral oncogene homolog fusion gene (\n                      <jats:italic>BCR\u2010ABL<\/jats:italic>\n                      ) was confirmed in all patients by FISH or RT\u2010PCR (the 190\u2010kDa protein [p190] construct was present in 49 patients [77%], and the p210 fusion transcript construct was present in 15 patients [23%]). The presence of a supernumerary Ph chromosome was correlated with a higher incidence of CD20 (B\u2010lymphocyte antigen, nonglycosylated phosphoprotein) expression (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001), whereas the p210 construct was correlated with aberrant CD25 expression (\n                      <jats:italic>P<\/jats:italic>\n                      = .05). Outcomes were not influenced by the degree of karyotypic complexity (including the presence or absence of a supernumerary Ph chromosome), CD20 expression, or myeloid antigen expression (CD13, CD33 [myeloid lineage transmembrane receptor], CD66c). CD25 expression was associated with inferior survival in univariate analysis (\n                      <jats:italic>P<\/jats:italic>\n                      = .051) but not in multivariate analysis (\n                      <jats:italic>P<\/jats:italic>\n                      = .092).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In the context of intensive, TKI\u2010based chemotherapy, the immunophenotypic, karyotypic, and molecular heterogeneity of Ph\u2010positive ALL no longer influences outcome. Cancer 2011. \u00a9 2011 American Cancer Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.25978","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T20:01:15Z","timestamp":1299096075000},"page":"4009-4017","source":"Crossref","is-referenced-by-count":42,"title":["Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B\u2010lymphoblastic leukemia in the era of tyrosine kinase inhibitors"],"prefix":"10.1002","volume":"117","author":[{"given":"Jesse","family":"Jaso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.11.3995"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232124"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2006.01.007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.12.2983.2983"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009148847"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1536"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04736.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/344251a0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1968.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403324"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP8G5RMTWUEMUU"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402504"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403714"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402060"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983559"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400836"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2861"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2007.02.004"},{"key":"e_1_2_6_23_2","first-page":"171","volume-title":"World Health Organization Classification of Tumors Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues","author":"Borowitz MJ","year":"2008"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2958"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.6506"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586"},{"key":"e_1_2_6_28_2","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene MC","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_29_2","volume-title":"ISCN 2005: An International System for Human Cytogenetic Nomenclature","author":"Shaffer LG","year":"2005"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800026"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_32_2","first-page":"163","article-title":"Evaluation of survival data and 2 new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"J R Stat Soc."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_6_34_2","first-page":"2118","article-title":"Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience","volume":"8","author":"Boldt DH","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.3.795"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404497"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010306"},{"issue":"2","key":"e_1_2_6_39_2","first-page":"195","article-title":"Immunochemotherapy with rituximab in adult CD20 B\u2010precursor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT","volume":"94","author":"Hoelzer D","year":"2009","journal-title":"Hematologica"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.984.984"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11891"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011221"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.147.147"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-052373"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25978","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:20:23Z","timestamp":1760271623000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":43,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1002\/cncr.25978"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25978","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}